Cellectar Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cellectar Biosciences has a total shareholder equity of $26.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $42.9M and $16.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$40.03m |
Equity | US$26.17m |
Total liabilities | US$16.74m |
Total assets | US$42.91m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NV4's short term assets ($41.4M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: NV4's short term assets ($41.4M) exceed its long term liabilities ($474.3K).
Debt to Equity History and Analysis
Debt Level: NV4 is debt free.
Reducing Debt: NV4 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NV4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NV4 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22% each year